ArticleNature biomedical engineering2026
Anchored random reverse primer sequencing for quantitative detection of novel gene fusions.
Xuehao Xiu, Yi Wu, Jiangxue Li, Dongfa Lin, Xiao Sun, Xinglei Su, Zhi Weng, Xiaolei Zuo, Xiurong Yang, Chunhai Fan and 3 more
Abstract read
In one paragraphArticle in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Xuehao Xiu *School of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0003-0799-6683 Yi Wu *School of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0009-0003-1951-495X Jiangxue Li *School of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dongfa LinSchool of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiao SunDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xinglei SuSchool of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhi WengSchool of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0003-0136-1978 Xiaolei ZuoInstitute of Molecular Medicine Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital School of Medicine, School of Chemistry and Chemical Engineering, New Cornerstone Science Laboratory, Frontiers Science Center for Transformative Molecules, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0001-7505-2727 Xiurong YangSchool of Chemistry and Chemical Engineering, New Cornerstone Science Laboratory, Frontiers Science Center for Transformative Molecules, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chunhai FanSchool of Chemistry and Chemical Engineering, New Cornerstone Science Laboratory, Frontiers Science Center for Transformative Molecules, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-7171-7338 Yudong WangDepartment of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. wangyudong@shsmu.edu.cn.ORCID http://orcid.org/0000-0002-9455-4471 David Yu ZhangBiostate AI, Inc., Houston, TX, USA.
Ping SongSchool of Biomedical Engineering, Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China. songpingsjtu@sjtu.edu.cn.ORCID http://orcid.org/0000-0001-5947-4604 Funding
National Natural Science Foundation of China (National Science Foundation of China) 22174094
6 · The paper itselfAbstract
Identifying novel gene fusions is critical for cancer diagnosis and drug development. While a few advanced methods have shown the capability to detect gene fusions involving unknown partners, comprehensive detection of gene fusions, especially of those with low copy numbers, remains a challenge. Indeed, most current panel-based sequencing methods fall short in reliability and cost efficiency. Here we present a method for detecting potentially novel gene fusions using anchored random reverse primers (ARRP) during PCR-based library construction, allowing the simultaneous capture of mutations and RNA splicing variants. Furthermore, the combination with blocker displacement amplification technology enables a median of 22-fold allele enrichment for gene fusions, achieving a limit of detection ~10-fold lower than that of current technologies and resulting in an 8-fold cost reduction. Using ARRP-seq, we identify numerous novel fusions in 98 clinical tissue samples, showcasing its diagnostic potential in prostate cancer and capacity for personalized diagnostics in cervical cancer.
Indexed as
DNA PrimersGene FusionFemaleGene LibraryHumansMutationPolymerase Chain ReactionProstatic NeoplasmsUterine Cervical NeoplasmsDNA Primers
What OpenQuestion holds
Textmetadata
Read underepoch 390